Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 28, 2006

Pharmacopeia and Schering-Plough Extend Collaboration

  • Pharmacopeia and Schering-Plough extended their collaboration until April of 2007. The terms of the extension call for Schering-Plough to continue to pay Pharmacopeia research funding for 10 full-time chemistry employees.

    Schering-Plough will also pay preclinical, clinical, and regulatory milestones as long as therapeutic candidates resulting from the collaboration advance to commercialization. Further, Pharmacopeia will continue to receive royalty payments on sales of any therapeutic products resulting from the collaboration.

    The goal of the collaboration is to deliver development-ready therapeutic candidates for the Schering-Plough pipeline. The companies agreed to extend the collaboration to continue to advance one of the ongoing programs toward this goal.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »